XOMA Royalty (NASDAQ:XOMA) Shares Pass Above 200 Day Moving Average – Should You Sell?

Shares of XOMA Royalty Corporation (NASDAQ:XOMA) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $28.63 and traded as high as $35.60. XOMA Royalty shares last traded at $33.87, with a volume of 44,397 shares.

Wall Street Analysts Forecast Growth

XOMA has been the subject of several recent research reports. Zacks Research lowered XOMA Royalty from a “strong-buy” rating to a “hold” rating in a research report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of XOMA Royalty in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised XOMA Royalty from a “hold” rating to a “buy” rating in a research report on Monday, August 11th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $69.50.

XOMA Royalty Stock Performance

The firm has a market cap of $409.49 million, a P/E ratio of -21.85 and a beta of 1.02. The company has a debt-to-equity ratio of 1.41, a quick ratio of 4.88 and a current ratio of 4.88. The business’s 50-day simple moving average is $35.69 and its 200 day simple moving average is $28.63.

XOMA Royalty (NASDAQ:XOMA) last announced its earnings results on Wednesday, August 13th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.60. The business had revenue of $13.13 million for the quarter, compared to analysts’ expectations of $9.39 million. XOMA Royalty had a positive return on equity of 2.63% and a negative net margin of 27.57%. As a group, equities analysts predict that XOMA Royalty Corporation will post -1.41 earnings per share for the current year.

Insider Activity at XOMA Royalty

In related news, CFO Thomas M. Burns sold 4,330 shares of XOMA Royalty stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $35.99, for a total transaction of $155,836.70. Following the sale, the chief financial officer owned 30,079 shares of the company’s stock, valued at approximately $1,082,543.21. This trade represents a 12.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 9.10% of the stock is owned by insiders.

Institutional Investors Weigh In On XOMA Royalty

Several hedge funds and other institutional investors have recently modified their holdings of the business. GAMMA Investing LLC lifted its stake in XOMA Royalty by 1,063.8% in the first quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 1,585 shares during the period. Tower Research Capital LLC TRC grew its stake in XOMA Royalty by 203.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,523 shares during the last quarter. JPMorgan Chase & Co. boosted its position in XOMA Royalty by 13.9% in the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 543 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of XOMA Royalty in the second quarter worth $116,000. Finally, Deutsche Bank AG raised its stake in shares of XOMA Royalty by 5,087.9% during the 1st quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 6,309 shares during the last quarter. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.